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The article by Hernandez and colleagues in this edition of the journal is a good example of a 
methodologically sound cost effectiveness analysis (1). Given the scarcity of health care resources and 
that most patients do not pay for health care at the point of consumption, alternative mechanisms are 
required for making health care resource allocation decisions.  
 
Cost effectiveness analysis provides an analytical framework for assessing the costs and benefits of 
interventions thus providing information to facilitate such decisions. Cost effectiveness analysis 
incorporates both concerns for efficiency and concerns for equity, with the assumption that society will 
value health gains the same irrespective of which individuals accumulate such gains.  Through the 
correct application and interpretation of such analyses, efficient and equitable allocation decisions can 
be made leading to improved levels of health across our population.  
 
Despite the increasing adoption of these techniques in decision making and the increasing volume of 
related publications, concerns with the methodology and potential bias within cost effectiveness 
analysis have been raised (2). This has been particularly pertinent due to the preponderance of industry 
sponsored studies within the literature, whose result generally favour the sponsor’s product. The article 
by Hernandez and colleagues is independent of industry sponsorship which provides some comfort 
given the potential biases identified in industry sponsored studies. (3, 4)   This is illustrated by the 
conflicting results within the current paper when compared to a previous study with direct industry 
sponsorship (5).  It should be noted that in the previous study published in the American Heart Journal, 
although co-authors have industry affiliations, no direct statement of conflict of interest is made 
highlighting a continued difficulty in assessing the independence of published studies. 
 
The article provides an illustration of the conduct of three methodological developments within the area 
of cost effectiveness analysis; the conduct of stratified analysis; of probabilistic analysis and of 
sequential analysis. 
 
Within the paper, results are provided for two patient strata:  patients with creatinine clearance 
between 50 and 95ml/min and patients with creatinine clearance >95ml/min. Results are derived by 
running the analysis including edoxaban for patients in the former category and excluding edoxaban for 
patients in the latter category.  Stratified cost effectiveness analysis is extremely insightful for decision 
makers, as cost effectiveness is often not a binary response across an entire patient population (6, 7). 
Rather it is conditional upon a number of factors relating to the nature of the patient population.  
Decision-makers have recognized the likely heterogeneity in cost effectiveness by making differential 
funding decisions within a patient population. Stratified analysis is required which parses a population 
into smaller, more homogeneous subgroups; with analysis conducted for each distinct subgroup.  It 
provides not only richer information to decision makers but a more precise estimate of cost 
effectiveness (8) 
 
The present analysis does not assume that parameter values will change across the two subgroups 
considered.  This is not a preferred approach.  If stratified analysis is required, it is preferable that where 
heterogeneity in input parameters is recognised, it should be fully incorporated (7).  Heterogeneity may 
relate to differences in all or merely a subset parameters within the model. In the analysis, there are 
instances where data is likely to vary across potential subgroups and rather than the heterogeneity 
recognized through appropriate stratification; data are combined. For example, the annual probability of 
extracranial bleeding is available for HAS-BLED score 3, 4 and 5.  It would have been informative to 
conduct analysis based on stratification by HAS-BLED score both to provide richer context to the results 
and a more precise estimate of the cost effectiveness across the patient population.  
 
The analysis by Hernandez and colleagues incorporates probabilistic sensitivity analysis (PSA). Within a 
PSA, data parameters are not presented by point estimates but through probability distributions which 
characterize their underlying uncertainty.  Probabilistic analysis is conducted through a Monte Carlo 
simulation whereby costs and outcomes for each alternative are obtained by re-running the model using 
random parameter values drawn from each parameter’s prescribed probability distribution.  This is 
repeated a number of times (in this example 10,000 times) and the expected values of costs and effects 
are estimated. (9) The results of the PSA are presented through a Cost Effectiveness Acceptability Curve 
which graphically presents the probability that each alternative is optimal for different values of a 
quality adjusted life year (QALY).  (9) The methodology adopted by Hernandez and colleagues is of a high 
standard.  The choice of distributions and methods for deriving expected values all meet desired 
standards.  
 
There are strong arguments that probabilistic analysis should not be relegated to a sensitivity analysis 
but rather should be the basis for the primary analysis.  This is due to the potential likely non-linear 
relationships between parameters and expected values, leading to the likelihood that probabilistic 
analysis will give different estimates than a simple deterministic analysis (10).  Thus, deterministic 
analyses can lead to non-optimal decisions (11).  Given the characteristics of decision analytic models in 
health care, especially Markov models, there is potential for discordance between the results of 
probabilistic models and deterministic models.  It is hoped that future cost effectiveness analyses 
published within the journal are encouraged to use probabilistic analysis as the basis for the primary 
results. 
 
To facilitate decision maker`s determination of the optimal therapy, Hernandez and colleagues present 
their results through a sequential analysis (12).  The purpose of cost effectiveness analyses is to allow 
decision makers to determine which therapy is optimal – that is, to identify which option is the best use 
of our scarce health care resources.  Analyses rarely can definitively determine which therapy is optimal 
as that is determined by a decision makers threshold in terms of their willingness to pay for a unit of 
health benefit (i.e. QALY)`- henceforth lambda.   
 
With a sequential analysis, one first removes all dominated (i.e. therapies that are more costly and less 
beneficial) from consideration.   For this analysis, dabigatran and rivaroxaban are removed.  Thus, only 
the following strategies are potentially optimal; warfarin, apixaban and edoxaban.  Which is optimal is 
ultimately a function of lambda.  A sequential analysis presents a sequence of incremental cost 
effectiveness ratios (ICER) for a less costly comparator compared to the next most costly comparator; 
excluding all dominated comparators. In the analysis for patients with creatinine clearance between 50 
and 95 ml/min, the ICER for edoxaban versus warfarin is $77,565 and, for apixaban versus edoxaban, it 
is $108,631.  Thus, the analysis facilitates a decision, in that if the decision maker`s lambda is less than 
$77,565 warfarin is optimal, if it is greater than $108,631 apixaban is optimal and if it lies in between 
edoxaban is optimal.  
 
Thus, the interpretation of analyses is highly dependent on a decision maker`s lambda.  The valuation of 
lambda however is a controversial topic.  Many authors have cited thresholds of either $50,000 or 
$100,000 per QALY for US decision makers (13).  Recently arguments have been made to increase the 
threshold based on both the World Health Organization`s stance on this issue and on historical research 
relating to the value of health gains from medical care (13, 14). These analyses have suggested lambda 
between $100,000 and $297,000. 
   
Such approaches ignore that health care decisions, whether they are made within a public or private 
based insurance system, work within a constrained budget.  Therefore, lambda should represent; what 
we forego by funding one technology rather than another; i.e. the opportunity cost of investing in one 
health care intervention over, another given current rates of expenditure.  Thus, to provide efficient and 
equitable health care, decision makers must actively identify or search for the relevant threshold not as 
suggested above, set such a threshold as suggested above (15) 
 
Recent work from the UK has attempted to estimate lambda empirically (16). The results from this 
analysis suggest a value of lambda substantially lower than those suggested above.  Based on 
expenditure in 2008, the value of lambda was £12,936 per QALY.  Based on a simple currency conversion 
for this threshold none of the newer oral anticoagulants can be considered cost effective.  Whether such 
a threshold is a close approximation for an appropriate value of lambda for US decision makers will 
depend on a variety of factors including the relative efficiency of the health care system and the relative 
levels of health care expenditure.  
 
Decision makers who are unhappy with the value of a  QALY identified by research such as that 
conducted by Claxton and colleagues must recognise that failure to adopt such thresholds ultimately 
means that other patients will bear the opportunity costs of such inefficient and inequitable decisions.  
There is of course a solution to raising the value of lambda; increased health insurance premiums or tax 
revenue devoted to health care.  
 
In conclusion, the cost effectiveness analysis presented in this issue of the journal is a good contribution 
highlighting the methodological developments in the area.  It is hoped that further research will fully 
embrace both the use of probabilistic and stratified analyses, whilst further methodological research will 
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